Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Amylyx Pharmaceuticals表示，關鍵的3期LUCIDITY將評估FDA同意的主要結果，即降低低血糖事件，並設計以儘可能與之前2期試驗設計更加接近。
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
艾默力製藥表示，關鍵的3期LUCIDITY將評估FDA同意的主要結局，即低血糖事件的減少，並設計得儘可能與之前的2期試驗設計相匹配。